Recent News about Valitor:
February 1, 2018
Valitor is proud to announce that we have received a seed investment from The House Fund. These funds will augment our current SBIR funding by accelerating the commercialization of our lead therapeutic product for indications in ophthalmology.
May 8, 2017
Valitor presented the its first preclinical data at the 2018 Associate for Research in Vision and Ophthalmology conference in Baltimore, MD. This report demonstrated a substantial increase in intravitreal half-life and extended efficacy for their lead Anti-VEGF compound intended to treat indications in ophthalmology.
December 13, 2016
Valitor was awarded the 2016 PharmaDirections Jumpstart Grant for California, presented at the California Life Sciences Institute's Fall Showcase event. This award recognizes one California start up company in the Life Sciences each year that is likely to make a significnat impact on their target market. The award includes consulting and project management that will help us develop a product development and viable commercial plan.
September 8, 2016
Valitor has been awarded a Phase I SBIR grant from the National Eye Institute. This project is designed to apply our technology towards localized and sustained treatments in ophthalmology. Specifically, we will validate a long-acting anti-VEGF drug to treat diabetic macular edema.
June 1, 2016
Valitor has recruited and hired Livia Brier, PhD to join our team as Director of Nonclinical research. Livia is a recent graduate from UC Berkeley’s Molecular and Cell Biology doctoral program with extensive experience in biochemistry and cell biology. She will be applying her experience in protocol development towards our expanding in vivo studies.
May 16, 2016
Valitor will be attending this year's BIO International Convention June 6-9 in San Francisco as a part of the NIH Innovation Zone. We were selected for this opportunity by the NIH to highlight the technologies under development using Phase II NIH SBIR Awards. We look forward to meeting with potential development partners, CROs, CMOs. Please stop by our kiosk (at booth 7253) if you are going to be there!